Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with concurrent chemoradiotherapy for cervical cancer
ChiCTR2100045220Phase 4Not yet recruiting
- Sponsor
- Pingdingshan First People's Hospital
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Pingdingshan First People's Hospital. Primary endpoint: Progression-free survival. Planned start May 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100045220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045220.